4D Molecular Therapeutics, Inc. (FDMT)
收市後：
- Zacks
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -13.24% and 100.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Reuters
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy. The stock hit an over two-year high of $35.61 after the company released interim data on Saturday from the trial that tested the gene therapy, 4D-150, in patients with wet age-related macular degeneration (AMD), a leading cause of vision loss among older adults. Wet AMD is a long-lasting disorder that causes blurred vision or a blind spot in the central vision due to fluid or blood leaking into the macula.
